The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: Rationale for its methodology and a review of the effectiveness of switching antipsychotics

Schizophrenia Bulletin

Volumn 41, Issue 3, 2015, Pages 549-558

  Leucht, Stefan ^a   Winter Van Rossum, Inge ^b   Heres, Stephan ^a   Arango, Celso ^c   Fleischhacker, W Wolfgang ^d   Glenthøj, Birte ^e   Leboyer, Marion ^f,g,h   Leweke, F Markus ⁱ   Lewis, Shôn ^j   McGuire, Phillip ^k   Meyer Lindenberg, Andreas ^g   Rujescu, Dan ^l   Kapur, Shitij ⁱ   Kahn, René S ^b   Sommer, Iris E ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Mental Health Center Glostrup   (Denmark)

^f INSERM U955   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h FONDATION FONDAMENTAL   (France)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

more..

Author keywords

Algorithm; Amisulpride; First episode; Nonresponse; Olanzapine; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ARTICLE; HUMAN; MEDLINE; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; EUROPE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; PSYCHOTIC DISORDERS; STANDARDS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MANAGEMENT; EUROPE; HUMANS; MULTICENTER STUDIES AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SULPIRIDE;

EID: 84954157221     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv019     Document Type: Article

References (59)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-2196.
2. Fraguas D, Merchan-Naranjo J, del Rey-Mejias A, et al. A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. Schizophr Res. 2014;158:126-133.
3. Diaz I, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Psychiatry Res. 2013;206:181-187.
4. Faber G, Smid HG, Van Gool AR, Wiersma D, Van Den Bosch RJ. The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. Eur Psychiatry. 2012;27:275-280.
5. Jordan G, Lutgens D, Joober R, Lepage M, Iyer SN, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014;75:e566-e572.
6. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(suppl 9):5-9.
7. Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L. Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol. 2013;33:80-83.
8. Remington G, Agid O, Foussias G, Hahn M, Rao N, Sinyor M. Clozapine's role in the treatment of first-episode schizophrenia. Am J Psychiatry. 2013;170:146-151.
9. Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;62:441-449.
10. Kane JM, Honigfeld G, Singer J, Meltzer H, group atCCs. Clozapine for the treatment-resistant schizophrenic. A double- blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
11. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213-223.
12. Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment- resistant schizophrenia. Int Clin Psychopharmacol. 2006;21:21-28.
13. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol. 2000;15:121-131.
14. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155:914-920.
15. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull. 1993;29:309-314.
16. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology, revised (DHEW Publ No ADM 76-338). National Institute of Mental Health; 1976:218-222.
17. Overall JE, Gorham DR. The brief psychiatric rating Scale. Psychol Rep 1962;10:790-812.
18. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686-693.
19. Klimke A, Klieser E, Lehmann E, Miele L. Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry. 1993;26:25-29.
20. Shalev A, Hermesh H, Rothberg J, Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand. 1993;87:86-91.
21. Suzuki T, Uchida H, Watanabe K, et al. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?-A randomized, open-label study of algorithm- based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology. 2007;195:285-295.
22. Hatta K, Otachi T, Sudo Y, et al. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Res. 2011;128:127-135.
23. Hatta K, Otachi T, Fujita K, et al. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Schizophr Res. 2014;158:213-222.
24. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
25. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
26. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611-622.
27. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. Am J Psychiatry. 2007;164:415-427.
28. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163:2090-2095.
29. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res. 2009;107:22-29.
30. Kinon BJ, Chen L, scher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35:581-590.
31. Leucht S, Heres S. The Switch Study - efficacy of an early antipsychotic switch in case of poor initial response to the treatment of schizophrenia (NCT01029769). Clinicaltrialsgov. 2009.
32. Sanz-Fuentenebro J, Taboada D, Palomo T, et al. Randomized trial of clozapine vs. risperidone in treatment-naive firstepisode schizophrenia: results after one year. Schizophr Res. 2013;149:156-161.
33. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini- International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
34. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097.
35. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-1404.
36. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951-962.
37. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
38. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376.
39. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205:119-128.
40. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Therapy 1997;280:83-97.
41. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Experiment Res. 2000;280:73-82.
42. Bymaster F, Perry KW, Nelson DL, et al. Olanzapine: a basic science update. Br J Psychiatry. 1999;174(suppl 37):36-40.
43. Kane JM, Honigfeld G, Singer J, Meltzer H, group. atCCs. Clozapine for the treatment-resistant schizophrenic. A double- blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
44. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32:715-723.
45. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201:481-485.
46. Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003;160:1514-1516.
47. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive firstepisode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.
48. Girgis RR, Phillips MR, Li X, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011;199:281-288.
49. Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72:1439-1444.
50. Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42:607-618.
51. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
52. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci. 2010;12:393-407.
53. Beitinger R, Lin J, Kissling W, Leucht S. Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1643-1651.
54. Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacology. 2007;194:453-461.
55. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247-251.
56. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323-329.
57. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995;166:654-659.
58. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl 3):133-138.
59. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.